A Phase 2a, Open Label, Dose Escalation Study for Safety, Tolerability, and Efficacy of Hepatocyte Transplantation Into Periduodenal Lymph Nodes Among Subjects With End-Stage Liver Disease
Latest Information Update: 03 Apr 2024
At a glance
- Drugs LYG-LIV0001 (Primary) ; Prednisone; Tacrolimus
- Indications Renal failure
- Focus Adverse reactions; Therapeutic Use
- Sponsors LyGenesis
- 02 Apr 2024 According to a LyGenesis media release, the first patient has been dosed in this trial.
- 24 Oct 2023 According to a LyGenesis media release, the has raised more than $19M in a Series A-2 financing round led by Prime Movers Lab. This funding will enable to complete this trial.
- 19 Sep 2023 Planned End Date changed from 31 Dec 2023 to 7 Aug 2026.